RT Journal Article
SR Electronic
T1 Long-Term Duration of Antibody Response to SARS CoV-2 in One of the Largest Slums of Buenos Aires
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.05.21253010
DO 10.1101/2021.03.05.21253010
A1 Pagotto, Vanina
A1 Luna, Lorena
A1 Salto, Julieta
A1 Manslau, Magdalena Wagner
A1 Figar, Silvana
A1 Mistchenko, Alicia S.
A1 Boyero, Georgina Carciofi
A1 Weinberger, Natacha
A1 ,
A1 Gómez Saldaño, Ana María
A1 Alponte, Carla Alpire
A1 Alarcón, Patricia Auza
A1 Tarqui, Ayelén Copa
A1 Cortez, Sheila
A1 Gallardo, Pamela
A1 Pinaya, Janeth Gemio
A1 Navarro, Ángeles Hernandez
A1 Maccio, Alejandro
A1 Mosqueda, Paula
A1 Neme, Nicole
A1 Quispe, Bania
A1 Bernal, Emilio Ramírez
A1 Soria, Thelma
A1 Arce, Angélica Fernández
A1 Gamarnik, Andrea
A1 de Quirós, Fernán González Bernaldo
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.05.21253010.abstract
AB The durability of the antibody response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has not been fully elucidated. We have performed a cross-sectional study in one of the largest slums of Buenos Aires, Barrio Padre Mugica in June 2020, detecting a seroprevalence of 53.4%. To evaluate the persistence of the humoral response against SARS-CoV-2 in this area, we designed a second study assessing only the people that were IgG positive in the first survey. The IgG levels against the full spike (S) protein in 175 individuals that were seropositive, at least 6 months before, were evaluated in a second survey. The positivity rate was 92.0%, 161 from 175 individuals remained IgG positive. We observed a contraction in the overall IgG levels measured by ELISA. The median IgG dropped 62% from June to December 2020. Most of the individuals tested (87%) reported to be asymptomatic or oligo-symptomatic. No difference was found between men and women, but people aged less than 50 showed a lower IgG level in each period compared to older individuals. Our data indicate sustained humoral immunity for at least 6 months in a specific socio-economical setting in a population that was mainly asymptomatic for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04673279Funding StatementThe National and local Ministries of Health provided medical supplies for the survey and for the virology laboratory to perform the ELISA test for SARS-COV-2 antibodies detection. The COVIDAR group provided the Serokits for sampling and the ELISA COVIDAR IgG kits, supported by FOCEM and Asoc. SAND. None of the funding sources provided economical support for the data collection, statistical analysis, or were used to write the manuscript, or to submit it for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Review board of the "Childern Hospital, Dr. Ricardo Gutierrez", Argentina.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot yet decided